Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GPR183 | P32249 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18626468 | 0.88 | HRH3 (0.51) | MAP4K4CYP2C9ALOX15TSHRCYP2C19 | |
| SCHEMBL19008145 | 0.87 | MAP4K4 (0.52) | MAP4K4CYP2C9ALOX15TSHRCYP2C19 | |
| SCHEMBL15587587 | 0.84 | MAP4K4 (0.52) | MAP4K4CYP2C9ALOX15TSHRCYP2C19 | |
| SCHEMBL17896301 | 0.84 | MAP4K4 (0.51) | MAP4K4CYP2C9ALOX15TSHRCYP2C19 | |
| SCHEMBL17896303 | 0.81 | MAP4K4 (0.53) | MAP4K4MEN1KMT2A | |
| SCHEMBL18626504 | 0.80 | LMNA (0.46) | MAP4K4CYP2C9ALOX15TSHRCYP2C19 | |
| SCHEMBL23544888 | 0.80 | TSHR (0.52) | CYP2C9ALOX15TSHRCYP2C19CYP2D6 | |
| SCHEMBL19008143 | 0.80 | ALDH1A1 (0.49) | MAP4K4CYP2C9ALOX15TSHRCYP2C19 | |
| SCHEMBL15587584 | 0.80 | MAP4K4 (0.50) | MAP4K4CYP2C9ALOX15TSHRCYP2C19 | |
| SCHEMBL19016222 | 0.80 | MAP4K4 (0.50) | MAP4K4CYP2C9ALOX15TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9855269-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-9592235-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2017-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | FLT4, FLT1, KDR | MAP4K4 662/4885CYP2C9 667/4885ALOX15 2911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.